SCHEMBL13010017

SCHEMBL13010017

COCC1OC(n2cnc3c(N)ncnc32)C(O)C1OCOc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 4/20 0.60
▸ ADORA3 P0DMS8 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ DPP4 P27487 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ SLC28A1 O00337 1/20 0.53
▸ MAP3K7 O43318 1/20 0.53
▸ SLC28A2 O43868 1/20 0.53
▸ GAPDH P04406 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ ADORA2A P29274 1/20 0.53
▸ ADORA2B P29275 1/20 0.53
▸ STAT6 P42226 1/20 0.53
▸ PI4KA P42356 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ PI4K2B Q8TCG2 1/20 0.53
▸ DOT1L Q8TEK3 1/20 0.53
▸ SLC29A1 Q99808 1/20 0.53
▸ PI4K2A Q9BTU6 1/20 0.53
▸ SLC28A3 Q9HAS3 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13009986 0.93 ADORA1 (0.60) ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2
SCHEMBL13009973 0.86 ADORA1 (0.56) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL24292047 0.85 ADORA3 (0.61) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL8626028 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL12646732 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL18521951 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL12015181 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL21999056 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL22399463 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1
SCHEMBL12590125 0.85 ADORA3 (0.64) ADORA1ADORA3SMN1; SMN2DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317714-A1 COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317714-A1 COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS DCLRE1B, RNASE1, AGO2 ADORA1 3979/4885ADORA3 3760/4885SMN1; SMN2 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback